Acorda Therapeutics, Inc.

Equities

ACOR

US00484M7002

Biotechnology & Medical Research

Delayed Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
13.21 USD +10.92% Intraday chart for Acorda Therapeutics, Inc. +9.09% -12.45%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
North American Morning Briefing : Investors -2- DJ
Acorda Therapeutics, Inc. to Regain Global Commercialization Rights to FAMPYRA by January 2025 CI
Transcript : Acorda Therapeutics, Inc., Q3 2023 Earnings Call, Nov 13, 2023
Earnings Flash (ACOR) ACORDA THERAPEUTICS Posts Q3 Revenue $27.7M MT
Acorda Therapeutics, Inc. Provides Revenue Guidance for the Full Year 2023 CI
Acorda Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Acorda Therapeutics Announces Biopas Laboratories Submission to Regulatory Agencies in Six Latin American Countries for Approval of INBRIJA CI
Acorda Therapeutics Surges 22% in Premarket Activity Thursday After Sliding 7.3% in Previous Regular Trading Session MT
Transcript : Acorda Therapeutics, Inc., Q2 2023 Earnings Call, Aug 08, 2023
Earnings Flash (ACOR) ACORDA THERAPEUTICS Reports Q2 Revenue $29.7M MT
Acorda Therapeutics, Inc. Reaffirms Revenue Guidance for the Full Year 2023 CI
Acorda Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Acorda Therapeutics Regains Compliance with Nasdaq Listing Rule on Minimum Bid Price MT
Acorda Therapeutics, Inc. Announces Jeff Randall Step Down as Board and Head of Audit Committee CI
Transcript : Acorda Therapeutics, Inc. - Special Call
Acorda Therapeutics Completes 1-for-20 Reverse Stock Split MT
Acorda Therapeutics to Implement 1-for-20 Reverse Stock Split MT
MannKind Hires Burkhard Blank as CMO MT
Acorda Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Transcript : Acorda Therapeutics, Inc., Q1 2023 Earnings Call, May 11, 2023
Earnings Flash (ACOR) ACORDA THERAPEUTICS Reports Q1 Revenue $22.3M MT
Acorda Therapeutics, Inc. Reaffirms Earnings Guidance for the Year 2023 CI
Top Midday Gainers MT
Acorda Therapeutics, Hangzhou Chance Pharmaceuticals Sign Deal to Sell Parkinson's Disease Drug in China MT
Acorda Therapeutics, Inc. and Hangzhou Chance Pharmaceuticals Co. Ltd. Announces Agreement to Commercialize Inbrija®? in China CI
Chart Acorda Therapeutics, Inc.
More charts
Acorda Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing therapies that restore function and enhance the lives of people with neurological disorders. The Company uses its ARCUS pulmonary delivery system, which is a technology platform designed to deliver medication through inhalation that is used in the development of a variety of inhaled medicines. The Company's commercial products include INBRIJA (levodopa inhalation powder) and AMPYRA (dalfampridine). Inbrija is an inhaled levodopa (L-dopa) for intermittent treatment of OFF episodes, also known as OFF periods in people with Parkinson's disease treated with carbidopa/levodopa regimen. Inbrija utilizes its ARCUS platform for inhaled therapeutics. AMPYRA (dalfampridine) is an extended-release tablet formulation of dalfampridine as a treatment to enhance walking in patients with multiple sclerosis (MS). Ampyra is marketed as Fampyra outside the United States by Biogen International GmbH.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
  1. Stock
  2. Equities
  3. Stock Acorda Therapeutics, Inc. - Nasdaq
  4. News Acorda Therapeutics, Inc.
  5. Acorda Therapeutics : Completes 1-for-6 Reverse Stock Split